Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers

Bhoj Raj Singh
  • Infection and Drug Resistance, March 2018, Dove Medical Press
  • DOI: 10.2147/idr.s163186
The author haven't yet claimed this publicationThe author haven't yet claimed this publication
open access logoRead Publication

http://dx.doi.org/10.2147/idr.s163186

In partnership with: